The Japanese in vitro diagnostics (IVD) company Sysmex plans to merge with U.K.-based molecular genetics firm Oxford Gene Technology (OGT). Under the terms of their agreement, Sysmex will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain. Currently, Sysmex develops, produces, and sells integrated instruments, reagents, and software used for IVD and is a global supplier in hematology, hemostasis, and urinalysis. Acquiring OGT will enable Sysmex to enter the cytogenetics market with fluorescence in situ hybridization (FISH) and array comparative genomic hybridization products. Sysmex expects that this move will also strengthen its technology base in molecular genetics through OGT’s next-generation sequencing reagent development capabilities. Additionally, research and development teams from OGT and Sysmex plan to collaborate to develop an automated system for FISH testing, while also aiming to expand opportunities further in genetic testing in the field of rare diseases and liquid biopsies.